GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » Cash-to-Debt

FFNTF (4Front Ventures) Cash-to-Debt : 0.01 (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is 4Front Ventures Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 4Front Ventures's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, 4Front Ventures couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for 4Front Ventures's Cash-to-Debt or its related term are showing as below:

FFNTF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 0.07   Max: No Debt
Current: 0.01

During the past 13 years, 4Front Ventures's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.07.

FFNTF's Cash-to-Debt is ranked worse than
97.45% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs FFNTF: 0.01

4Front Ventures Cash-to-Debt Historical Data

The historical data trend for 4Front Ventures's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

4Front Ventures Cash-to-Debt Chart

4Front Ventures Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.16 0.14 0.07 0.02

4Front Ventures Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.02 0.01 0.01

Competitive Comparison of 4Front Ventures's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4Front Ventures's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's Cash-to-Debt falls into.



4Front Ventures Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

4Front Ventures's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

4Front Ventures's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4Front Ventures  (OTCPK:FFNTF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


4Front Ventures Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


4Front Ventures Business Description

Traded in Other Exchanges
Address
7010 E. Chauncey Lane, Suite 235, Phoenix, AZ, USA, 85054
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to owned dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
Executives
Leonid Gontmakher director, officer: Chief Executive Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick officer: See Remarks C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane director 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano other: Consultant 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati director 28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams officer: Chief Financial Officer 108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt director C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel director 3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut officer: Chief Investment Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham officer: Chief Operating Officer 5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey director ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey officer: Chief Financial Officer C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202